Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.

Human psychopharmacology - 1 Jun 2002

Stedman Catherine A M, Begg Evan J, Kennedy Martin A, Roberts Rebecca, Wilkinson Timothy J

Abstract excerpt

AIMS: The aims of this study were to determine if patients with SSRI-related hyponatraemia were (1) genetically poor metabolizers of CYP2D6, and/or (2) had excessive plasma concentrations of the SSRI antidepressant. METHODS: Plasma DNA from 20 people with hyponatraemia attributable to fluoxetine or paroxetine was analysed for the CYP2D6 alleles *1-*16. Trough plasma concentrations of fluoxetine and norfluoxetine,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Depressive Disorder

Share to Fluoxetine

Share to Paroxetine

Share to Risk Factors

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 12404686
DOI: 10.1002/hup.394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.PMID 12404686Read ↗

Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants.Semantic proximity Read ↗

Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.Semantic proximity Read ↗

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.Semantic proximity Read ↗

Voriconazole-induced hyponatraemia associated with homozygous CYP2C19*2 genotype.Semantic proximity Read ↗

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.Semantic proximity Read ↗

Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial.Semantic proximity Read ↗

Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.Semantic proximity Read ↗

Cytochrome P4502D6 genotype does not determine response to clozapine.Semantic proximity Read ↗

Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT.Semantic proximity Read ↗

Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers.Semantic proximity Read ↗

Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.